Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | RAMP3 | O60896 | 10/20 | 0.44 |
| ▸ | CALCR | P30988 | 10/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.43 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.43 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580299 | 1.00 | MAPK8 (0.61) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL30974409 | 0.88 | MAPK8 (0.55) | MAPK8MAPK9MAPK10KEAP1VIPR2 | |
| SCHEMBL29965273 | 0.87 | MAPK8 (0.61) | MAPK8MAPK9MAPK10KEAP1VIPR2 | |
| SCHEMBL30242269 | 0.87 | MAPK8 (0.51) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL30171144 | 0.87 | KDM1A (0.48) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL29786765 | 0.85 | MAPK8 (0.56) | MAPK8MAPK9MAPK10KEAP1VIPR2 | |
| SCHEMBL31480031 | 0.85 | MAPK8 (0.49) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL30686009 | 0.85 | MAPK8 (0.49) | MAPK8MAPK9MAPK10KEAP1 | |
| SCHEMBL6520003 | 0.85 | MAPK8 (0.45) | MAPK8MAPK9MAPK10KEAP1RAMP3 | |
| SCHEMBL29687469 | 0.85 | MAPK8 (0.48) | MAPK8MAPK9MAPK10KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| CN-114787142-B | Compounds as cyclin dependent kinase 9 inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230102081-A1 | COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2023-03-30 | — | — | US | disclosed |
| EP-4074699-A1 | COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-7250496-B2 | Bioinformatically detectable group of novel regulatory genes and uses thereof | ROSETTA GENOMICS LTD. (IL) | 2007-07-31 | — | — | US | disclosed |
| US-20060003322-A1 | Bioinformatically detectable group of novel regulatory genes and uses thereof | GENOPTIX, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230102081-A1 | COMPOUND AS CYCLIN-DEPENDENT KINASE 9 INHIBITOR AND USE THEREOF | CDK9, CDK4, CDKL4 | MAPK8 156/4885MAPK9 25/4885MAPK10 75/4885 |
| US-12570607-B2 | Compound as cyclin-dependent kinase 9 inhibitor and use thereof | CDK9, CDK4, CDKL4 | MAPK8 289/4885MAPK9 40/4885MAPK10 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.